Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
biotech deals
Biotech
Novo inks $4.7B Akero buyout to bag late-phase MASH prospect
At $54 a share, the upfront deal value represents a 19% premium to Akero’s average stock price over the past 30 days.
Nick Paul Taylor
Oct 9, 2025 8:21am
AstraZeneca, Algen Biotechnologies pen $555M AI pact
Oct 6, 2025 8:00am
Ignota buys Kronos' pipeline to rescue shelved programs
Oct 6, 2025 5:45am
Merck opts in on Evaxian's preclinical vaccine candidate
Sep 25, 2025 7:00am
Biopharma biobucks decline, while upfront deal payments rise
Sep 24, 2025 11:30am
Angelini signs $550M-plus neuro pact with South Korean biotech
Sep 22, 2025 1:47pm
